Eight Years after Jesse’s Death, Are Human Research Subjects Any Safer?
By Paul Gelsinger and Adil E. Shamoo,
Hastings Center Report
| 04. 04. 2008
It has been more than eight years since Jesse Gelsinger, Paul's son, died in a gene therapy clinical trial. But despite the press exposure and public outcry that followed, no progress has been made in fixing the broken system of protections for human research subjects. These people are no safer today than they were eight years ago-they are still at serious risk of exploitation and harm.
Many things stand in the way of better protection, but perhaps the greatest obstacle is the lack of adequate federal oversight. Not all human research is subject to federal regulations, since the regulations apply only to studies that are federally funded or that involve new drugs and devices for which applications have been filed with the Food and Drug Administration. An estimated 30 percent of studies are not covered. In
contrast, each and every experiment involving animals is regulated by the federal government under the Animal Welfare Act.
Further, the federal oversight that does exist offers minimal protection. Last year, a report by the inspector general of the Department of Health and Human Services...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Alexandra Marquez, NBC News | 03.13.2026
“Donald Trump” by Gage Skidmore is licensed under CC BY-SA 2.0
President Donald Trump on Thursday blamed “the genetics” of assailants in a string of recent attacks across the country. He made the comments after attacks at a...